Making the Call in Type 2 Diabetes
GLP-1 Receptor Agonists and Reducing Stroke Risk
Cardiovascular disease (CVD) is the leading cause of death among patients with type 2 diabetes (T2D). Among the potential cardiovascular complications of T2DM, stroke is a particularly high risk for patients, especially given the aging population. Increasing rates of diabetes, hypertension, and obesity are also placing a larger population of younger patients at risk for stroke. Some antidiabetic therapies, including certain glucagon-like peptide-1 (GLP-1) receptor agonists, can reduce the CVD risks in patients with T2D and contribute to secondary prevention. Expert faculty discussions in this Phone-a-Friend series will address specific challenge related to the management of patients with T2D, the risk of stroke, and the roles of GLP-1 receptor agonists.
This series is jointly provided by Global Education Group and Integritas Communications.
This series is supported by an educational grant from Novo Nordisk Inc.
Module 1
credit amount 0.25
credit type CME/CE
expiration 09/29/2023
Module 2
credit amount 0.25
credit type CME/AANP
expiration 10/18/2023
Webcast Series
Module 3
credit amount 0.25
credit type CME/AANP
expiration 11/11/2023
Webcast Series
Module 4
credit amount 0.25
credit type CME/AANP
expiration 11/30/2023
Resource
Making the Call in Type 2 Diabetes
